Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma
- PMID: 28656502
- PMCID: PMC5487900
- DOI: 10.1007/s11912-017-0603-8
Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma
Abstract
Cholangiocarcinoma is a rare form of gastrointestinal cancer with a poor prognosis. Patients often present with biliary obstruction or non-specific abdominal pain, and a high proportion of patients have advanced disease at initial diagnosis. The goal of this review is to discuss treatment options for patients with advanced bile duct tumours focusing on radioembolisation (RE) and its impact on overall survival. RE provides a therapeutic option for patients with unresectable cholangiocarcinoma. However, although systemic chemotherapy has demonstrated a survival benefit in randomised controlled trials, there is limited supporting evidence for the use of RE in this setting. Studies are mostly limited to single-centre, small cohorts with variable outcome measures. Additionally, patients included in these studies received a variety of previous therapies including chemotherapy, surgery or alternative intra-arterial therapy; therefore, a true assessment of overall survival benefit is difficult.
Keywords: Advanced; Chemotherapy; Cholangiocarcinoma; Intrahepatic; Liver radioembolisation (RE); Treatment.
Conflict of interest statement
Conflict of Interest
Pavan Najran declares that he has no conflict of interest.
Angela Lamarca declares that she has no conflict of interest.
Damian Mullan declares that he has no conflict of interest.
Mairéad G. McNamara declares that she has no conflict of interest.
Thomas Westwood has received compensation from BTG for service as a consultant.
Richard A. Hubner declares that he has no conflict of interest.
Jeremy Lawrence has received compensation from Sirtex Medical for service as a consultant.
Prakash Manoharan has received compensation from Sirtex Medical and TheraSpheres for service as a consultant.
Jon Bell declares that he has no conflict of interest.
Juan W. Valle has received compensation from Sirtex Medical for service as a consultant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Funding
Angela Lamarca was funded by the Spanish Society of Medical Oncology (SEOM) Fellowship Grant.
Similar articles
-
The multidisciplinary management of gastrointestinal cancer. Biliary tract cancers: from pathogenesis to endoscopic treatment.Best Pract Res Clin Gastroenterol. 2007;21(6):1015-29. doi: 10.1016/j.bpg.2007.09.005. Best Pract Res Clin Gastroenterol. 2007. PMID: 18070701 Review.
-
Update on the management of cholangiocarcinoma.Dig Dis. 2014;32(5):570-8. doi: 10.1159/000360507. Epub 2014 Jul 14. Dig Dis. 2014. PMID: 25034290 Free PMC article. Review.
-
Cholangiocarcinoma.Crit Rev Oncol Hematol. 2009 Mar;69(3):259-70. doi: 10.1016/j.critrevonc.2008.09.008. Epub 2008 Nov 1. Crit Rev Oncol Hematol. 2009. PMID: 18977670 Review.
-
Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice.J Gastroenterol Hepatol. 2009 Nov;24(11):1745-52. doi: 10.1111/j.1440-1746.2009.05915.x. Epub 2009 Sep 25. J Gastroenterol Hepatol. 2009. PMID: 19780885
-
[Cholangiocarcinoma: epidemiology and global management].Rev Med Interne. 2008 Aug;29(8):642-51. doi: 10.1016/j.revmed.2007.11.010. Epub 2008 Feb 12. Rev Med Interne. 2008. PMID: 18272258 Review. French.
Cited by
-
Progress toward improving outcomes in patients with cholangiocarcinoma.Curr Treat Options Gastroenterol. 2021 Mar;19(1):153-168. doi: 10.1007/s11938-021-00333-2. Epub 2021 Jan 30. Curr Treat Options Gastroenterol. 2021. PMID: 33883870 Free PMC article.
-
Liver transplantation for intrahepatic cholangiocarcinoma: a propensity score-matched analysis.Sci Rep. 2023 Jun 30;13(1):10630. doi: 10.1038/s41598-023-37896-2. Sci Rep. 2023. PMID: 37391482 Free PMC article.
-
Network pharmacology- and cell-based assessments identify the FAK/Src pathway as a molecular target for the antimetastatic effect of momordin Ic against cholangiocarcinoma.Heliyon. 2024 Jun 3;10(11):e32352. doi: 10.1016/j.heliyon.2024.e32352. eCollection 2024 Jun 15. Heliyon. 2024. PMID: 38961933 Free PMC article.
-
FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib.Onco Targets Ther. 2019 Nov 6;12:9303-9307. doi: 10.2147/OTT.S218796. eCollection 2019. Onco Targets Ther. 2019. PMID: 31807010 Free PMC article.
-
Inhibition of miR-10a-5p suppresses cholangiocarcinoma cell growth through downregulation of Akt pathway.Onco Targets Ther. 2018 Oct 15;11:6981-6994. doi: 10.2147/OTT.S182225. eCollection 2018. Onco Targets Ther. 2018. PMID: 30410355 Free PMC article.
References
-
- Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. Springer-Verlag: New York; 2010.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical